Better Robotics Stock: UiPath or Zebra Technologies

Zebra Technologies’ Q1 results showed $1.49B in sales (+14.3% YoY) and EPS of $2.78 (+3.8% YoY), alongside an upgraded 2026 outlook (sales +10% to +14%; non-GAAP EPS $18.30–$18.70). UiPath also strengthened its profitability profile, posting true GAAP EPS of $0.04 (vs -$0.04 a year ago) and 17.3% YoY revenue growth to $418.4M, with Q2 deals increasingly driven by AI/agentic automation (16 of top 20 deals used AI). Both names were highlighted as value opportunities after valuation compression and with shareholder returns supported by buybacks (UiPath announced a new $500M repurchase program after completing $1B, while Zebra repurchased $300M each of the prior two quarters).

Analysis

ZBRA looks like the cleaner earnings-quality winner. The market is likely still underestimating how much of the upside comes from mix shift and not just cyclical volume: once hardware pulls through, the software/RFID/machine-vision attach creates a higher-margin, stickier revenue stream that tends to re-rate faster than plain industrial exposure. That also pressures lower-end point solutions and systems integrators that depend on fragmented vendor stacks; if Zebra keeps bundling more of the workflow, competitors with thinner service and hardware economics lose pricing power first.

PATH is more interesting as a sentiment reset than a fundamental breakout. Profitability removes the classic “AI kills RPA” bear case, but the bigger issue is whether agentic automation becomes a standalone budget line or gets absorbed into Microsoft, ServiceNow, or SAP bundles. In other words, the upside is real if PATH becomes the orchestration layer for complex governance-heavy workflows; the downside is that AI makes the category more valuable while making the economics easier for larger platforms to commoditize.

The key risk is timing. ZBRA should keep working over the next 1-3 quarters if industrial spend, freight, and memory costs stay benign, but a PMI rollover or margin slippage would quickly cap the multiple because the stock is now being judged on sustained operating leverage. For PATH, the falsifier is simple: if the next two quarters show profitability without ARR reacceleration or meaningful AI conversion, the market will treat the margin story as expense discipline rather than durable growth, and the stock stays range-bound despite buybacks.

Key Decisions for Investors

• Long ZBRA on pullbacks over the next 1-3 months; target is continued multiple support from margin expansion and buybacks. Falsify the thesis if gross margin slips back below the low-50% area or management cuts FY guidance.
• Pair trade: long ZBRA / short PATH for 3-6 months. ZBRA has clearer near-term earnings leverage and a tangible margin pathway; PATH still needs proof that agentic AI translates into durable ARR rather than pilot activity. Cover if PATH shows >15% ARR growth acceleration and sustained GAAP profitability.
• Do not chase PATH outright here; make it a watchlist name for the next earnings cycle. Prefer entry only if the stock remains weak despite a quarter with AI deal conversion and no guidance reduction.
• Use ZBRA as a long against industrial automation underperformers in the supply chain and logistics stack (e.g., hardware-lite workflow names) if channel checks confirm end-market restocking; the read-through is stronger for warehouse and healthcare automation than for broad industrial capex.